Latest Close
₹830.15
-0.84%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹881.71
200 DMA
₹751.68
1 year gain / loss
+₹112.80(+15.72%)
₹717.35 → ₹830.15· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and much more. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its product line includes human nutrition, animal health, and industrial products. Under human nutrition, it offers active pharmaceutical ingredients, dietary supplements, probiotics, and enzymes, among others.
Market Cap
₹46,669.77 Cr
P/E
81.06×
Sector 31.19× · above
P/B
15.34×
Sector 7.75× · above
EV / EBITDA
50.16×
Sector 16.09× · above
ROE
19.45%
Sector 22.23%
ROCE
26.70%
Sector 23.67%
ROA
16.80%
Sector 12.40%
Cash Flow / Profit
1.43×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 443.11 -33.1% | 144.58 | 119.94 -36.8% |
| Mar 2026 | 662.15 +45.0% | 277.92 | 189.76 +104.4% |
| Dec 2025 | 456.68 -23.7% | 130.47 | 92.82 -46.5% |
| Sep 2025 | 598.26 | 229.6 | 173.43 |
Dividend
25 Jun 2026 · ₹2